Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631371 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 791
- Enrollment target
NCT00631371: Completed Phase 3 study, sponsored by Pfizer.
NCT00631371 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 791 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00631371, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 791 participants
- Enrollment target
Study Summary
Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.
Primary Outcome
PFS was defined as the interval from the date of randomization until the earlier date of progression or death. Progression was assessed by independent imaging reviewers using Response Evaluation Criteria in Solid Tumors (RECIST) criteria which is 20% increase in sum of longest diameter of target lesions from nadir (the lowest blood counts); measurable increase in non-target lesion; appearance of new lesions.
Interventions
- DRUG Bevacizumab
- DRUG Temsirolimus
- DRUG Interferon-Alfa 9MU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 791 participants |
| Start Date | 2008-04 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
What the finished NCT00631371 record still lists
NCT00631371 is an interventional study that assigns participants to a tested intervention. The registered 791 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00631371 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00631371 about?
NCT00631371 is a clinical study titled "Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects". Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed),...
What is the current status of trial NCT00631371?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 791 participants. The study started on 2008-04. Estimated completion is 2015-04.
What interventions are being tested in trial NCT00631371?
The interventions under investigation include: Bevacizumab (DRUG), Temsirolimus (DRUG), Interferon-Alfa 9MU (DRUG).
Who is sponsoring clinical trial NCT00631371?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00631371's enrollment target sits among peer trials
791 429th of 2000 higher than 1,572 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03424005 · 792 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- NCT05866081 · 792 participants · NA
Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
- NCT06722352 · 792 participants · NA
Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)
- NCT04967989 · 790 participants · Phase 3
Clarifying the Optimal Application of SLT Therapy Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia